Pixium Vision Receives €1.8 Million Research Tax Credit from French Government

Pixium Vision SA has announced the reception of a €1.8 million Research Tax Credit from the French government. The funds received will enable the company to extend its cash runway until the end of September 2023, offering greater flexibility to pursue long-term funding opportunities that align with its strategic ambitions, as stated in a company news release.

“We remain convinced that the Prima System could offer real hope to dry AMD (geographic atrophy) and retinal disease patients, and this cash injection will provide Pixium with enhanced resources strengthening our position in partnering discussions with investors," Lloyd Diamond, CEO of Pixium Vision, said in a company news release. "It is becoming increasingly evident that in the future, patients suffering from other profound central vision impairment should also be able to benefit from the Prima Bionic Vision System.”

“The recent FDA breakthrough device designation granted this past March 2023 gives us further confidence in the potential of photovoltaic neurostimulation to restore vision in patients suffering from retinal degenerative diseases,” he added.

Pixium Vision remains dedicated to their pivotal European study, which aims to evaluate the safety and clinical advantages of the wireless PRIMA System in individuals suffering from geographic atrophy caused by age-related macular degeneration. With the completion of 38 required implantations in the "PRIMAvera study" towards the end of 2022, the release of topline data is anticipated by the end of 2023, followed by EU market approval in 2024.